Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Mebufotenin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.84 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.79 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.79 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.79 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.68 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.67 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.63 |
| ▸ | HTR1D | P28221 | 8/20 | 0.79 |
| ▸ | HTR1B | P28222 | 8/20 | 0.79 |
| ▸ | HTR1A | P08908 | 7/20 | 0.79 |
| ▸ | HTR6 | P50406 | 4/20 | 0.79 |
| ▸ | HTR7 | P34969 | 3/20 | 0.79 |
| ▸ | HTR5A | P47898 | 3/20 | 0.79 |
| ▸ | HTR1E | P28566 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.79 |
| ▸ | HTR3B | O95264 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | HTR1F | P30939 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebufotenin SCHEMBL30199593 | 1.00 | KMT2A (0.84) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL7205139 | 0.92 | KMT2A (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Fumaric Acid SCHEMBL29435351 | 0.91 | HTR6 (0.79) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Fumaric Acid SCHEMBL23927856 | 0.91 | HTR6 (0.79) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL27221706 | 0.89 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL132733 | 0.89 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL31098269 | 0.89 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL29351950 | 0.89 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL25344818 | 0.89 | HTR1A (0.68) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Fumaric Acid SCHEMBL30729598 | 0.88 | HTR1A (0.69) | KMT2AHTR1DHTR1BHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-11 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | KMT2A 542/4885HTR2A 5/4885HTR2C 3/4885 |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | KMT2A 542/4885HTR2A 5/4885HTR2C 3/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | KMT2A 542/4885HTR2A 5/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.